Truist initiated coverage of BeOne Medicines (ONC) with a Buy rating and $400 price target The firm expect Brukinsa’s revenue stream to sustainably support the company’s operations and drive BeOne Medicines toward the guided positive free cash flow by 2025, the analyst tells investors in a research note. The company’s leadership position in CLL – chronic lymphocytic leukemia – is well-solidified by Brukinsa’s differentiation and the franchise’s comprehensive growth strategy, including proprietary next-wave assets such as sonrotoclax and BTK CDAC, Truist added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines Secures $1 Billion Financing Agreement
- BeOne Medicines price target raised to $408 from $395 at RBC Capital
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- BeOne Medicines: Buy Rating Driven by Robust Global Vision and Strong Financial Performance
- BeOne Medicines price target raised to $420 from $398 at Jefferies